NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravisAarhus, ...

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder ...

Researchers have identified a protein that’s critical to the development of skeletal muscle mass and strength and the tissue’s ability to metabolize glucose. They say their findings may lead to ...

Muscle loss (atrophy) due to inactivity is common after illness, injury, hospitalization or falls, and becomes increasingly ...

Researchers identified a molecular pathway that can limit muscle repair, a finding that may guide future muscular dystrophy treatments.

The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in ...

Skeletal muscle is the type of muscle that controls movement. Problems with these muscles can be minor, life-threatening, or ongoing problems that make it hard to perform basic daily activities.

A study by Indiana University School of Medicine researchers sheds new light on the development and treatment of a rare form of muscular dystrophy. The study's findings were recently published in ...

Skeletal muscle loss is a risk factor for developing dementia, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). Skeletal muscles ...

The MarketWatch News Department was not involved in the creation of this content. -- NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in ...